vs
Side-by-side financial comparison of Evolv Technologies Holdings, Inc. (EVLV) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $38.5M, roughly 1.8× Evolv Technologies Holdings, Inc.). Evolv Technologies Holdings, Inc. runs the higher net margin — 28.3% vs -49.0%, a 77.3% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 32.3%).
Sentient Technologies was an American artificial intelligence technology company based in San Francisco. Sentient was founded in 2007 and received over $143 million in funding at different points after its inception. As of 2016, Sentient was the world's most well-funded AI company. It focused on e-commerce, online content and trading.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
EVLV vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.5M | $70.6M |
| Net Profit | $10.9M | $-34.6M |
| Gross Margin | 48.4% | — |
| Operating Margin | -20.7% | -56.7% |
| Net Margin | 28.3% | -49.0% |
| Revenue YoY | 32.3% | 81958.1% |
| Net Profit YoY | 169.2% | 54.9% |
| EPS (diluted) | $0.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.5M | — | ||
| Q3 25 | $42.9M | $70.6M | ||
| Q2 25 | $32.5M | — | ||
| Q1 25 | $32.0M | — | ||
| Q4 24 | $29.1M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $25.2M | — | ||
| Q1 24 | $22.2M | — |
| Q4 25 | $10.9M | — | ||
| Q3 25 | $-1.8M | $-34.6M | ||
| Q2 25 | $-40.5M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-15.7M | — | ||
| Q3 24 | $-30.4M | — | ||
| Q2 24 | $3.4M | — | ||
| Q1 24 | $-11.3M | — |
| Q4 25 | 48.4% | — | ||
| Q3 25 | 49.7% | — | ||
| Q2 25 | 49.8% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | 57.5% | — | ||
| Q3 24 | 57.8% | — | ||
| Q2 24 | 58.5% | — | ||
| Q1 24 | 54.8% | — |
| Q4 25 | -20.7% | — | ||
| Q3 25 | -20.1% | -56.7% | ||
| Q2 25 | -53.8% | — | ||
| Q1 25 | -45.0% | — | ||
| Q4 24 | -64.9% | — | ||
| Q3 24 | -70.0% | — | ||
| Q2 24 | -88.7% | — | ||
| Q1 24 | -98.8% | — |
| Q4 25 | 28.3% | — | ||
| Q3 25 | -4.2% | -49.0% | ||
| Q2 25 | -124.6% | — | ||
| Q1 25 | -5.3% | — | ||
| Q4 24 | -54.0% | — | ||
| Q3 24 | -111.3% | — | ||
| Q2 24 | 13.6% | — | ||
| Q1 24 | -50.8% | — |
| Q4 25 | $0.07 | — | ||
| Q3 25 | $-0.01 | — | ||
| Q2 25 | $-0.25 | — | ||
| Q1 25 | $-0.01 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $-0.19 | — | ||
| Q2 24 | $0.02 | — | ||
| Q1 24 | $-0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.1M | $490.9M |
| Total DebtLower is stronger | $28.6M | — |
| Stockholders' EquityBook value | $119.4M | $503.0M |
| Total Assets | $304.4M | $577.1M |
| Debt / EquityLower = less leverage | 0.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $49.1M | — | ||
| Q3 25 | $56.2M | $490.9M | ||
| Q2 25 | $36.9M | — | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $51.9M | — | ||
| Q3 24 | $56.0M | — | ||
| Q2 24 | $56.5M | — | ||
| Q1 24 | $81.0M | — |
| Q4 25 | $28.6M | — | ||
| Q3 25 | $28.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $119.4M | — | ||
| Q3 25 | $102.2M | $503.0M | ||
| Q2 25 | $92.7M | — | ||
| Q1 25 | $121.1M | — | ||
| Q4 24 | $117.7M | — | ||
| Q3 24 | $129.0M | — | ||
| Q2 24 | $151.2M | — | ||
| Q1 24 | $139.8M | — |
| Q4 25 | $304.4M | — | ||
| Q3 25 | $304.3M | $577.1M | ||
| Q2 25 | $280.4M | — | ||
| Q1 25 | $256.0M | — | ||
| Q4 24 | $268.1M | — | ||
| Q3 24 | $278.5M | — | ||
| Q2 24 | $269.1M | — | ||
| Q1 24 | $280.0M | — |
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.6M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.6M | — | ||
| Q3 25 | $3.5M | $-84.6M | ||
| Q2 25 | $2.1M | — | ||
| Q1 25 | $-2.5M | — | ||
| Q4 24 | $3.2M | — | ||
| Q3 24 | $3.7M | — | ||
| Q2 24 | $-21.6M | — | ||
| Q1 24 | $-16.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.43× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.31× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
